a clear trendP = 0.002
For the olmesartan group, however, there was a clear trend toward a lower incidence of MAU in the lower HR quartiles ( P = 0.002 for trend).
For the olmesartan group, however, there was a clear trend toward a lower incidence of MAU in the lower HR quartiles ( P = 0.002 for trend).
These results are in agreement with data previously reported by Böhm et al, who showed a trend toward increasing MAU with increasing HR in patients with hypertension and/or cardiovascular disease. 14 , 22 , 23 Similarly, Hillis et al 15 noted an increasing risk of microvascular complications, including nephropathy, with increasing HR in patients with type 2 diabetes.